Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Rezpegaldesleukin for Treating Moderate-to-Severe Atopic Dermatitis in Adults

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying atopic dermatitis, a condition that causes the skin to become red, itchy, and inflamed. The study will evaluate a treatment called rezpegaldesleukin, also known by its code name NKTR-358. This treatment is given as a solution for injection under the skin. The trial will also use a placebo for comparison purposes.

The purpose of the study is to assess how effective and safe rezpegaldesleukin is for adults with moderate-to-severe atopic dermatitis. Participants in the study will receive either the treatment or a placebo over a period of 54 weeks. The study will monitor changes in the severity of the skin condition and any side effects that may occur.

Throughout the study, participants will have regular check-ups to track their progress and any changes in their condition. The study aims to provide valuable information on whether rezpegaldesleukin can be a beneficial treatment option for those suffering from moderate-to-severe atopic dermatitis.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial Visit and Randomization

    Upon joining the study, the patient will attend an initial visit where eligibility is confirmed. This includes a diagnosis of atopic dermatitis for at least 12 months and meeting specific severity criteria.

    The patient will be randomly assigned to receive either the study medication, rezpegaldesleukin, or a placebo. This process is double-blind, meaning neither the patient nor the study team will know which treatment is being administered.

  2. Step 2

    Treatment Phase

    The patient will receive rezpegaldesleukin or placebo through a subcutaneous injection. The medication is administered as a solution for injection.

    The treatment will continue for a total of 54 weeks, with regular administration as per the study protocol.

  3. Step 3

    Monitoring and Assessments

    Throughout the study, the patient will undergo regular assessments to monitor the effectiveness and safety of the treatment. This includes measuring changes in the severity of atopic dermatitis using various scales such as EASI (Eczema Area and Severity Index) and vIGA-AD (Investigator's Global Assessment for Atopic Dermatitis).

    The patient will also be monitored for any adverse events or side effects that may occur during the study period.

  4. Step 4

    Follow-Up

    After completing the treatment phase, the patient will have follow-up visits to assess the long-term effects of the treatment and to ensure any side effects are managed appropriately.

    The study aims to evaluate the mean percent change in EASI from baseline at Week 16 and other secondary outcomes over the 54-week period.

Who can join the trial?

10 criteria

  • Provide written, informed consent to participate in the study and agree to follow the study procedures.
  • Agree to use highly effective contraceptives during the study.
  • Be a male or female between 18 and 70 years old on the day of signing the consent form. In some places, the legal age of consent might be higher than 18.
  • Have a diagnosis of Atopic Dermatitis (AD) for at least 12 months before the first screening visit. AD is a skin condition that causes itchy and inflamed skin.
  • Meet the following AD severity criteria:
    • EASI score of 16 or higher at both screening and randomization visits. EASI is a tool used to measure the severity of eczema.
    • vIGA-AD score of 3 or higher at both screening and randomization visits. vIGA-AD is a scale used to assess the overall severity of AD.
    • At least 10% of the body surface area (BSA) affected by AD at both screening and randomization visits.
    • Be a candidate for systemic therapy, which means treatment that affects the entire body, and have a history of not responding well to topical medications (creams or ointments applied to the skin) within 6 months before the first screening visit.
    • Have a history of not achieving good disease control with topical medications, defined as mild disease or better, after using at least a medium potency topical corticosteroid (TCS) for at least 4 weeks or the maximum recommended duration.
    • Have a history of significant adverse reactions to TCS, such as skin thinning, allergic reactions, or effects on the whole body, that make further treatment not advisable according to the study doctor.

Who cannot join the trial?

9 criteria

  • Patients who have previously used biologic treatments for their condition cannot participate.
  • Patients with other skin conditions that might interfere with the study results are not eligible.
  • Patients with a history of severe allergic reactions to similar medications are excluded.
  • Patients with certain infections or diseases that could affect the study are not allowed to join.
  • Pregnant or breastfeeding women cannot take part in the study.
  • Patients who are currently participating in another clinical trial are not eligible.
  • Patients with a history of drug or alcohol abuse may be excluded.
  • Patients with certain medical conditions that could interfere with the study results are not eligible.
  • Patients who are unable to follow the study procedures or attend study visits are excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Rezpegaldesleukin is a medication being studied for its effectiveness and safety in treating adults with moderate-to-severe atopic dermatitis, a type of skin condition. The trial aims to see how well this medication works in reducing the symptoms of the condition compared to not receiving the active treatment. Rezpegaldesleukin is being tested to understand its potential benefits for patients who have not previously been treated with biologic therapies.

What is already known about the treatment

Rezpegaldesleukin – This medication is administered through injection and is currently being studied in clinical trials for its effectiveness in treating moderate-to-severe atopic dermatitis. It is not yet widely available in medical practice, as it is still under investigation. The main therapeutic indication for rezpegaldesleukin is atopic dermatitis, a chronic skin condition characterized by inflammation and itching. At the molecular level, rezpegaldesleukin works by modulating the immune system to reduce inflammation, potentially improving skin symptoms. It is classified pharmacologically as an immunomodulatory agent.

Investigated diseases

Atopic Dermatitis – Atopic Dermatitis is a chronic skin condition characterized by dry, itchy, and inflamed skin. It often begins in childhood but can occur at any age. The disease tends to flare periodically and then subside. It is associated with a malfunction in the skin barrier, leading to increased sensitivity and susceptibility to irritants and allergens. The condition can cause significant discomfort and may affect sleep and quality of life. Environmental factors, stress, and genetic predisposition can influence its progression.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-507456-69-00Protocol code23-358-05Estimated enrolment555 patientsSponsorNektar Therapeutics

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.